Bendamustine Hydrochloride Patent Expiration
Bendamustine Hydrochloride was first introduced by Cephalon Inc
Bendamustine Hydrochloride Patents
Given below is the list of patents protecting Bendamustine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Vivimusta | US11707450 | Jul 29, 2042 | Azurity | |
| Vivimusta | US11844784 | Stable pharmaceutical compositions of bendamustine | Jul 29, 2042 | Azurity |
| Vivimusta | US12208086 | Stable pharmaceutical compositions of bendamustine | Jul 29, 2042 | Azurity |
| Vivimusta | US12419867 | Stable Pharmaceutical Compositions Of Bendamustine | Jul 29, 2042 | Azurity |
| Bendeka | US10052385 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9000021 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9034908 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9144568 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9572887 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9579384 | Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597397 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597398 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Bendeka | US9597399 | Formulations of bendamustine | Mar 15, 2033 | Eagle Pharms |
| Belrapzo | US8609707 | Formulations of bendamustine | Aug 11, 2031 | Eagle Pharms |
| Bendeka | US8609707 | Formulations of bendamustine | Aug 11, 2031 | Eagle Pharms |
| Treanda |
US8436190 (Pediatric) | Bendamustine pharmaceutical compositions | Apr 26, 2031 | Cephalon |
| Belrapzo | US10010533 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11103483 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11844783 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US11872214 | Formulations of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US12138248 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US12350257 | Formulations Of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US9265831 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US9572796 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Belrapzo | US9572797 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US10010533 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US11103483 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US11844783 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US11872214 | Formulations of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US12138248 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US12350257 | Formulations Of Bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9265831 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9572796 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Bendeka | US9572797 | Formulations of bendamustine | Jan 28, 2031 | Eagle Pharms |
| Treanda | US8436190 | Bendamustine pharmaceutical compositions | Oct 26, 2030 | Cephalon |
| Treanda |
US8344006 (Pediatric) | Liquid formulations of bendamustine | Mar 23, 2030 | Cephalon |
| Treanda |
US8445524 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda |
US8669279 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda |
US8883836 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda |
US9533955 (Pediatric) | Solid forms of bendamustine hydrochloride | Sep 26, 2029 | Cephalon |
| Treanda | US8344006 | Liquid formulations of bendamustine | Sep 23, 2029 | Cephalon |
| Treanda | US8445524 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda | US8669279 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda | US8883836 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Treanda | US9533955 | Solid forms of bendamustine hydrochloride | Mar 26, 2029 | Cephalon |
| Bendeka |
US8791270 (Pediatric) | Bendamustine pharmaceutical compositions |
Jul 12, 2026
(Expired) | Eagle Pharms |
| Treanda |
US8609863 (Pediatric) | Bendamustine pharmaceutical compositions |
Jul 12, 2026
(Expired) | Cephalon |
| Treanda |
US8791270 (Pediatric) | Bendamustine pharmaceutical compositions |
Jul 12, 2026
(Expired) | Cephalon |
| Treanda |
US8895756 (Pediatric) | Bendamustine pharmaceutical compositions |
Jul 12, 2026
(Expired) | Cephalon |
| Belrapzo | US8791270 | Bendamustine pharmaceutical compositions |
Jan 12, 2026
(Expired) | Eagle Pharms |
| Bendeka | US8791270 | Bendamustine pharmaceutical compositions |
Jan 12, 2026
(Expired) | Eagle Pharms |
| Treanda | US8609863 | Bendamustine pharmaceutical compositions |
Jan 12, 2026
(Expired) | Cephalon |
| Treanda | US8791270 | Bendamustine pharmaceutical compositions |
Jan 12, 2026
(Expired) | Cephalon |
| Treanda | US8895756 | Bendamustine pharmaceutical compositions |
Jan 12, 2026
(Expired) | Cephalon |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Bendamustine Hydrochloride's patents.
Latest Legal Activities on Bendamustine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Bendamustine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
| ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 21 May, 2025 | US8609863(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Oct, 2024 | US8436190(Litigated) |
| Payment of Maintenance Fee, 12th Year, Large Entity | 23 Oct, 2024 | US8445524(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 20 Jun, 2024 | US9533955 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 19 Jun, 2024 | US8344006 |
| Email Notification Critical
| 20 Dec, 2023 | US11844784 |
| Mail Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Patent eGrant Notification | 19 Dec, 2023 | US11844784 |
| Recordation of Patent Grant Mailed Critical
| 19 Dec, 2023 | US11844784 |
| Patent Issue Date Used in PTA Calculation Critical
| 19 Dec, 2023 | US11844784 |
Bendamustine Hydrochloride's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Bendamustine Hydrochloride:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
| ||||
| A Clinical Trial to Evaluate the Efficacy and Safety of TQB3909 Tablets Versus Investigator's Choice in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma | Kami Maddocks, MD | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE1 |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | National Cancer Institute (NCI) | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma | Eastern Cooperative Oncology Group | NA |
ACTIVE NOT RECRUITING
(May 1, 2026)
| PHASE2 |